摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-溴-4-(3-甲氧基丙氧基)苯 | 279262-34-9

中文名称
1-溴-4-(3-甲氧基丙氧基)苯
中文别名
——
英文名称
1-bromo-4-(3-methoxypropoxy)benzene
英文别名
——
1-溴-4-(3-甲氧基丙氧基)苯化学式
CAS
279262-34-9
化学式
C10H13BrO2
mdl
——
分子量
245.116
InChiKey
IBTRRSNXSNWLRO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    13
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE SYNTHASE DE GLUCOSYLCÉRAMIDE
    申请人:GENZYME CORP
    公开号:WO2014043068A1
    公开(公告)日:2014-03-20
    The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
    该发明涉及抑制葡萄糖鞘氨醇合成酶(GCS)的抑制剂,用于治疗代谢性疾病,如溶酶体贮积病,单独或与酶替代疗法、囊性疾病以及癌症的联合治疗。
  • Anilide derivative, production and use thereof
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US06235771B1
    公开(公告)日:2001-05-22
    This invention is to provide a compound of the formula: wherein R1 is an optionally substituted 5- to 6-membered ring; the ring A is an optionally substituted 6- to 7-membered ring; the ring B is an optionally substituted benzene ring; n is an integer of 1 or 2; Z is a chemical bond or a divalent group; R2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, (2) an optionally substituted nitrogen-containing heterocyclic ring group which may contain a sulfur atom or an oxygen atom as ring constituting atoms and wherein a nitrogen atom may form a quaternary ammonium, (3) a group binding through a sulfur atom or (4) a group of the formula:  wherein k is 0 or 1, and when k is 0, a phosphorus atom may form a phosphonium; and R5 and R6 are independently an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted amino group, and R5 and R6 may bind to each other to form a cyclic group together with the adjacent phosphorus atom, or a salt thereof , which is useful for antagonizing CCR5 and also for the prevention and treatment of infectious disease of HIV.
    这项发明提供了以下式的化合物: 其中R1是一个可选择取代的5至6成员环;环A是一个可选择取代的6至7成员环;环B是一个可选择取代的苯环;n是1或2的整数;Z是化学键或二价基团;R2是(1)一个可选择取代的氨基团,其中氮原子可以形成季铵盐,(2)一个可选择取代的含氮杂环环基团,可能含有硫原子或氧原子作为环构成原子,其中氮原子可以形成季铵盐,(3)通过硫原子结合的基团或(4)下式的基团: 其中k为0或1,当k为0时,磷原子可以形成磷铵盐;R5和R6分别是可选择取代的碳氢基团、可选择取代的羟基或可选择取代的氨基团,R5和R6可以结合在一起与相邻的磷原子形成环状基团,或其盐,用于拮抗CCR5并用于预防和治疗HIV感染疾病。
  • Tetrahydropyridines as renin inhibitors
    申请人:Speedel Experimenta AG
    公开号:EP1908471A1
    公开(公告)日:2008-04-09
    The application relates to novel substituted tetrahydropyridines of the general formulae (I) and (II) and the salts thereof, preferably the pharmaceutically acceptable salts thereof, in which Q, T, V and W have the meanings defined in the description, to a process for the preparation thereof and to the use of these compounds as medicines, especially as renin inhibitors.
    该申请涉及一种新型的取代四氢吡啶,其通式为(I)和(II)及其盐,优选为其药用可接受盐,其中Q、T、V和W的含义如描述中所定义,以及其制备方法和将这些化合物用作药物,特别是作为肾素抑制剂。
  • MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR
    申请人:HUANG Jiann-Jyh
    公开号:US20130190312A1
    公开(公告)日:2013-07-25
    Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    提供了调节Hec1/Nek2相互作用的化合物、组合物和方法。这些化合物破坏Nek2/Hec1结合,可能作为肿瘤治疗药物有用。
  • Modulators of Hec1 activity and methods therefor
    申请人:Taivex Therapeutics Corporation
    公开号:US08999983B2
    公开(公告)日:2015-04-07
    Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    提供了调节Hec1/Nek2相互作用的化合物、组合物和方法。这些化合物破坏Nek2/Hec1结合,可能作为治疗肿瘤疾病的化疗药物有用。
查看更多